Novel Therapy for Sepsis

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$231,235.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI072864-01
Award Id:
85290
Agency Tracking Number:
AI072864
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
COGNOSCI, INC., 79 T. W. Alexander Drive, RESEARCH TRIANGLE PARK, NC, 27709
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
141881727
Principal Investigator:
DALE CHRISTENSEN
(919) 765-0028
DCHRISTENSEN@COGNOSCI.COM
Business Contact:
MICHAEL VITEK
() -
mikevitek@cognosci.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Sepsis remains an important medical problem that results in over 200,000 deaths each year in the United States. Sepsis syndrome results in multisystem organ failure due to a systemic inflammatory response and activation of the blood clotting cascade. Efforts to develop effective therapeutics to treat sepsis have been disappointing with only one drug being approved. Recent evidence has implicated apolipoprotein E polymorphisms in modulating the systemic inflammatory respo nse, a response that may play an important role in the outcome of patients with sepsis syndrome where presence of the APOE4 allele is associated with increased risk of sepsis following elective surgical procedures and following cardiopulmonary bypass. Cogn osci Inc. has discovered an anti-inflammatory peptide known as COG133 that was demonstrated to suppress activation of and reduce secretion of inflammatory mediators. More recently, we have demonstrated that COG133 improved outcome in a preliminary sepsis s tudy using a murine cecal ligation-perforation model. In order to further pursue COG133 as a treatment for sepsis, we propose to complete evaluation of COG133 in more relevant single species bacteremia mouse models of sepsis. Sepsis syndrome induced by bot h gram positive (Staphylococcus aureus) and gram negative (Escherichia coli) bacterial species will be evaluated to determine the dose of COG133 required to reduce mortality. The optimized dose of COG133 will be used in further experiments to characterize disease progression through biochemical and histological analysis. Biochemical disease progression will be monitored through determination of systemic inflammatory cytokine levels (serum TNFa, Il-1?, IL-6 levels), clotting times and activation of cell sign aling (phospho-JNK, phospho-IRAK, phospho-P38). Successful demonstration of improved mortality, reduced harmful inflammatory responses, and reduced organ damage from clotting will lead to Phase II studies in baboons to evaluate efficacy in a primate model that was used for development of the only FDA approved therapeutic for treatment of sepsis syndrome.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government